5-氟-2-硝基苯甲酸乙酯 | 364-51-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氟-2-硝基苯甲酸乙酯
• 中文别名: 2-硝基-5-氟苯甲酸乙酯
• 英文名称: ethyl 5-fluoro-2-nitrobenzoate
• 英文别名: 5-fluoro-2-nitro-benzoic acid ethyl ester；5-Fluor-2-nitro-benzoesaeure-aethylester
• CAS: 364-51-2
• 化学式: C₉H₈FNO₄
• 分子量: 213.165
• InChiKey: LNFCVLHYTOGQEK-UHFFFAOYSA-N

物化性质

• 沸点：
  296.3±25.0 °C(Predicted)
• 密度：
  1.333±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  5-氟-2-硝基苯甲酸乙酯 在 10% palladium hydroxide on charcoal 、 氢气 、 sodium hydride 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 24.0h， 生成 ethyl 1-propyl-1,2-dihydro-4-hydroxy-6-fluoro-2-oxo-quinoline-3-carboxylate
  参考文献：
  名称：

  Design, synthesis and biological characterization of a new class of osteogenic (1H)-quinolone derivatives

  摘要：

  Smoothened (Smo) is the signal transducer of the Hedgehog (Hh) pathway and its stimulation is considered a potential powerful tool in regenerative medicine to treat severe tissue injuries. Starting from GSA-10, a recently reported Hh activator acting on Smo, we have designed and synthesized a new class of quinolone-based compounds. Modification and decoration of three different portions of the original scaffold led to compounds able to induce differentiation of multipotent mesenchymal cells into osteoblasts. The submicromolar activity of several of these new quinolones (0.4-0.9 mu M) is comparable to or better than that of SAG and purmorphamine, two reference Smo agonists. Structure-activity relationships allow identification of several molecular determinants important for the activity of these compounds. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.05.062
• 作为产物：
  描述：

  5-氟-2-硝基苯甲酸 在 氯化亚砜 作用下， 生成 5-氟-2-硝基苯甲酸乙酯
  参考文献：
  名称：

  The Synthesis of Some Alkyl and Dialkylaminoalkyl Esters of 2-Nitro-5-fluorobenzoic Acid and 2-Amino-5-fluorobenzoic Acid

  摘要：

  DOI：

  10.1021/ja01235a032

文献信息

• [EN] PIPERIDINE SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES WITH INHIBITORY ACTIVITY ON THE REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV)<br/>[FR] DÉRIVÉS DE PYRAZOLO[1,5-A]PYRIMIDINE SUBSTITUÉS PAR PIPÉRIDIN, AYANT UNE ACTIVITÉ INHIBITRICE SUR LA RÉPLICATION DU VIRUS RESPIRATOIRE SYNCYTIAL (RSV)
  申请人：JANSSEN SCIENCES IRELAND UC

  公开号：WO2016091774A1

  公开（公告）日：2016-06-16

  The invention concerns novel substituted bicyclic pyrazolo pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.

  这项发明涉及具有抗病毒活性的新型取代的双环吡唑嘧啶化合物，特别是对呼吸道合胞病毒（RSV）复制具有抑制活性的化合物。该发明还涉及制备这种新型化合物，包含这些化合物的组合物，以及用于治疗呼吸道合胞病毒感染的化合物。
• Process for the preparation of 5-fluoroanthranilic alkyl esters and/or
  申请人：Hoechst Aktiengesellschaft

  公开号：US05543550A1

  公开（公告）日：1996-08-06

  The present invention relates to a process for the preparation of 5-fluoroanthranilic alkyl esters and/or 5-fluoroanthranilic acid, which comprises dissolving a 3-fluorobenzoic alkyl ester in sulfuric acid and reacting the solution with a nitrating acid at from -10.degree. to 30.degree. C., then adding water, separating off the nitrated reaction product and reacting it with hydrogen at from 50.degree. to 120.degree. C. under elevated pressure in the presence of a catalyst comprising a metal of the platinum group and sulfur, and, if desired, removing 5-fluoroanthranilic alkyl esters by distillation and hydrolyzing them to give 5-fluoroanthranilic acid.

  本发明涉及一种制备5-氟基蒽酰基烷基酯和/或5-氟基蒽酰基酸的方法，包括将3-氟苯甲酸烷基酯溶解在硫酸中，并在-10℃至30℃的范围内将所述溶液与硝化酸反应，然后加入水，分离出硝化反应产物，并在铂族金属和硫的催化剂存在下，在50℃至120℃的升压条件下与氢反应，如有需要，通过蒸馏去除5-氟基蒽酰基烷基酯，并将其水解为5-氟基蒽酰基酸。
• PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY
  申请人：Reborna Biosciences, Inc.

  公开号：EP3816160A1

  公开（公告）日：2021-05-05

  A prophylactic or therapeutic agent for spinal muscular atrophy according to the present invention includes a compound represented by the formula (I) or a salt thereof: wherein: W1, W2, and W3 are each independently selected from the group consisting of C-R2, C-R3, C-Rc, and C-Rd, and are defined by one of the followings (i) to (iv): (i) when W3 is C-R2, then W1 is C-R3, W2 is C-Rc or N, and R1 is a hydrogen atom; (ii) when W3 is C-R3, then W1 is C-R2, W2 is C-Rc or N, and R1 is a hydrogen atom, C1-8 alkyl, or C1-8 alkoxy; (iii) when W1 is C-R2, then W2 is C-Rc or N, W3 is C-Rd, and R1 is an aliphatic heterocycle containing one or more nitrogen atoms, the aliphatic heterocycle being optionally substituted with a non-aromatic substituent; and (iv) when W2 is C-R2, W1 is C-Rc, W3 is C-Rd, and R1 is an aliphatic heterocycle containing one or more nitrogen atoms, the aliphatic heterocycle being optionally substituted with a non-aromatic substituent; R2 is a 6- or more membered aromatic ring optionally substituted with a non-aromatic substituent; R3 is an aliphatic heterocycle containing one or more nitrogen atoms, the aliphatic heterocycle being optionally substituted with a non-aromatic substituent; Q1 is selected from C-Ra and N; Q2 is selected from C-Rb and N; and Ra, Rb, Rc, and Rd are each independently selected from the group consisting of a hydrogen atom, halogen, C1-8 alkyl, C1-8 alkoxy, and a cyano group.

  根据本发明，脊髓性肌萎缩症的预防或治疗剂包括由式（I）代表的化合物或其盐： 其中 W1、W2 和 W3 各自独立地选自由 C-R2、C-R3、C-Rc 和 C-Rd 组成的组，并由以下(i)至(iv)之一定义： (i) 当 W3 为 C-R2 时，W1 为 C-R3，W2 为 C-Rc 或 N，R1 为氢原子； (ii) 当 W3 为 C-R3 时，则 W1 为 C-R2，W2 为 C-Rc 或 N，且 R1 为氢原子、C1-8 烷基或 C1-8 烷氧基； (iii) 当 W1 是 C-R2，则 W2 是 C-Rc 或 N，W3 是 C-Rd，且 R1 是含有一个或多个氮原子的脂族杂环，该脂族杂环任选被非芳香族取代基取代；以及 (iv) 当 W2 为 C-R2、W1 为 C-Rc、W3 为 C-Rd 且 R1 为含有一个或多个氮原子的脂族杂环时，该脂族杂环可任选被非芳香族取代基取代； R2 是一个 6 个或多个成员的芳香环，可任选被一个非芳香族取代基取代； R3 是含有一个或多个氮原子的脂族杂环，该脂族杂环可选择被非芳香族取代基取代； Q1 选自 C-Ra 和 N； Q2 选自 C-Rb 和 N；以及 Ra、Rb、Rc 和 Rd 各自独立地选自由氢原子、卤素、C1-8 烷基、C1-8 烷氧基和氰基组成的组。
• PIPERIDINE SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES WITH INHIBITORY ACTIVITY ON THE REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV)
  申请人：Janssen Sciences Ireland UC

  公开号：EP3230287A1

  公开（公告）日：2017-10-18
• US4801717A
  申请人：——

  公开号：US4801717A

  公开（公告）日：1989-01-31